January 6, 2026 – Talk Bio

Actionable Insights Powered by AI

Pfizer Inks $865M Discovery Deal with Cartography Biosciences for Tumor-Selective Antigens

2 days ago talkbio0Tagged cancer discovery, Cartography Biosciences, Collaboration, Pfizer, Pharma, tumor-selective antigens

Pfizer; Cartography Biosciences; pharma deal; tumor-selective antigens; cancer discovery; biotech collaboration

Vaccine Investors Stay Silent Amid Trump Administration’s Childhood Vaccine Schedule Cuts

2 days ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Childhood Vaccines, Recommendation, RFK gene, Trump vaccine schedule, vaccine overhaul

Trump vaccine schedule; RFK Jr.; CDC recommendations; childhood vaccines; vaccine overhaul

Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026

3 days ago talkbio0Tagged Aktis, IPO, methionine, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M

Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations

3 days ago talkbio0Tagged Amgen Uplizna, IgG4-Related Disease, Obexelimab, Phase 3 INDIGO, plunge, Zenas BioPharma

Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna

Argenx Appoints Karen Massey as New CEO in Leadership Transition

3 days ago talkbio0Tagged Argenx, CEO, Infrequent, Karen Massey, Leadership, Tim Van Hauwermeiren, Transition Mutation

argenx; Karen Massey; CEO; Tim Van Hauwermeiren; leadership transition; rare diseases; Vyvgart

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

3 days ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics

3 days ago talkbio0Tagged Acromegaly, Crinetics, enrollment forms, methionine, PALSONIFY, prescribers, Q4 2025, Revenue

Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers

Spotlight On: Five key oncology stories to watch in 2026

3 days ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology

Bayer Receives Breakthrough Therapy Designation in US and China for Sevabertinib in First-Line HER2-Mutant NSCLC

3 days ago talkbio0Tagged Bayer, Breakthrough Therapy Designation, CDE, China, First line treatment, HER2-mutant, Non-Small Cell Lung Carcinoma, sevabertinib, United States Food and Drug Administration

Bayer; sevabertinib; Breakthrough Therapy Designation; HER2-mutant NSCLC; FDA; China CDE; first-line treatment

Protara Therapeutics Receives FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Lymphatic Malformations

3 days ago talkbio0Tagged Breakthrough Therapy, Fast Track, Lymphatic Abnormalities, Lyophilized Inactivated Group A Streptococcus TARA-002, Pediatric brand name, Protara Therapeutics, United States Food and Drug Administration

Protara Therapeutics; TARA-002; FDA; Breakthrough Therapy; Fast Track; Lymphatic Malformations; Pediatric